Actualités

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader market did that week. Earned income depends on showing up. Dividend income depends on a board of directors ... Own 500 Shares of Pfizer and JNJ and Here’s Your Annual Dividend Income

Pfizer Inc. (NYSE:PFE) is one of the most undervalued NYSE stocks to invest in. On June 18, Pfizer announced that Chief Financial Officer Dave Denton will step down on August 15 to pursue a new professional opportunity in the consumer goods industry. The company has appointed Cecile Guegan, currently Senior Vice President of Finance for […]

Novo Nordisk (NYSE:NVO)'s majority owner has launched a large pan European research program focused on obesity and cardiometabolic diseases. The initiative aims to speed up research, support startups, and feed potential candidates into Novo Nordisk's future drug pipeline. Pfizer is expanding efforts in obesity treatments, including plans for a first in class monthly GLP 1 therapy and broader clinical trials. Novo Nordisk is a central player in obesity and diabetes care, and this new...

Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b pharmaceutical group is positioned, with value metrics and recent returns drawing closer scrutiny. See our latest analysis for Pfizer. Pfizer’s recent share price has softened, with the stock down 6.53% on a 90 day share price return basis, while the 1 year total shareholder return of 12.52% reflects a different experience for investors over a longer period. If Pfizer’s recent...

Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.

Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.

While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

Pfizer (PFE) reached $25.22 at the closing of the latest trading day, reflecting a -2.72% change compared to its last close.

The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.

Pfizer (PFE) named an interim head of finance on Thursday as it announced the departure of Chief Fin

In a filing with the Securities and Exchange Commission, Pfizer said Executive Vice President and Chief Financial Officer Dave Denton notified the company on June 16 that he will step down effective August 15.

Cecile Guegan will become interim CFO on Aug. 16 while Pfizer searches for a successor.

Dave Denton will leave in August as Pfizer works through its post-COVID reset.

Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index decreasing 0.9% and the Sta

Pfizer announced that Chief Financial Officer Dave Denton will leave the company in August to pursue an external opportunity. Senior Vice President Cecile Guegan has been appointed Interim CFO, effective upon Denton’s departure. The change affects Pfizer’s top financial leadership at a time when the company is focused on major pipeline investments and internal changes. For investors watching Pfizer (NYSE:PFE), this shift in financial leadership arrives with the stock trading at $25.92 and...

Market Catalyst Host Julie Hyman breaks down today's Trending Tickers, giving us the latest on Accenture (ACN), Pfizer (PFE), and Kroger (KR).

All three major US stock indexes rose in midday trading Thursday as investors assessed the signing o

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.

PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.

Pfizer Inc. (NYSE:PFE) shares edged lower on Thursday after the pharmaceutical giant revealed that Chief Financial Officer Dave Denton will step down from his position and leave the company in August.

GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.

Cecile Guegan will serve as interim CFO starting August 16 while Pfizer searches for a permanent replacement

Investing.com - U.S. stock futures ticked higher on Thursday, as the signing of an interim Middle East peace deal helped ease concerns sparked by the Federal Reserve’s hawkish policy outlook.

A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid dividends.

Dave Denton joined Pfizer in 2022 from Lowe’s Companies and is leaving for an unspecified “professional opportunity” in consumer goods, the company said.

Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.

The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.

Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.